Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05920798
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:03.271302+00:00
Published At
2026-04-06T00:00:00+00:00
Record Updated At
2026-04-06
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Fallopian Tube Carcinosarcoma", "Primary Peritoneal Carcinosarcoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Fallopian Tube Clear Cell Adenocarcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Carcinosarcoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Carcinosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-06"
protocolSection.identificationModule.nctId
"NCT05920798"
protocolSection.identificationModule.officialTitle
"MC220601, Folate Receptor Alpha Dendritic Cells (FR\u03b1DCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Fallopian Tube Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube High Grade Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian High Grade Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinosarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.